RESTYLANE LYFT PP
Generic Name and Formulations:
Hyaluronic acid 20mg/mL, 0.3% lidocaine; injectable gel implant.
Galderma Laboratories, Inc.
Indications for RESTYLANE LYFT:
Correction of moderate-to-severe facial folds and wrinkles (eg, nasolabial folds). Cheek augmentation and correction of age-related midface contour deficiencies.
See full labeling. Inject slowly with least amount of pressure necessary. Individualize. Wrinkles/folds: inject into the deep dermis to superficial subcutis; max 6mL per treatment. Cheek augmentation/midface deficiencies: (≤21yrs): not established; (>21yrs): give by subcutaneous or supraperiosteal injection; max 6mL per treatment. Both: may require repeat treatments to achieve desired effects.
History of anaphylaxis or presence of multiple severe allergies. Allergies to Gram (+) bacterial proteins. Bleeding disorders.
Should only be used by trained and experienced healthcare practitioners. Obtain patient's complete medical history prior to initiation. Avoid intravascular inj; discontinue immediately if changes in vision, signs of stroke, blanching of skin or unusual pain during or shortly after procedure occurs. Avoid implantation in vascular rich areas (eg, glabella, nose). Risk of infection. Defer if active inflammatory process or infection is present at specific sites. Use for lip augmentation or in areas other than nasolabial folds and midface area: not established. Concomitant epilation, UV irradiation, or laser, mechanical or chemical peeling procedures: not evaluated. Possible risk of an inflammatory reaction at implant site if laser treatment, chemical peeling, or any other procedure based on active dermal response is considered after Restylane Lyft or if product is given before skin has healed completely after such a procedure. Risk of herpes reactivation in patients with a history of herpetic eruption. Avoid excessive sun, UV lamp exposure, or extreme cold weather. Patients (<18yrs), pregnancy, nursing mothers: not established.
Caution with concomitant immunosuppressants or in those who have undergone therapy with thrombolytics, anticoagulants, or platelet aggregation inhibitors in the preceding 3wks. Increased bruising or bleeding at inj sites with concomitant aspirin, NSAIDs, St. John's Wort, high dose Vit. E; avoid.
Inj site reactions (eg, bruising, redness, swelling, pain, tenderness, itching); delayed inflammatory papules, hyperpigmentation, possible keloid formation, hypersensitivity reactions.
Single-use syringe—1 (w. needles)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|